2 results
Approved WMOPending
The primary objective is to evaluate the safety and efficacy of the PulseCath during support of patients with impaired ventricular function, for a period between 24 hours minimum and 14 days maximum. Safety will be assessed by the incidence of…
Approved WMOCompleted
The primary objective of this study is to determine the efficacy and safety of different doses of LCZ696 compared to valsartan. In addition, the efficacy and safety of AHU377 as compared to placebo is evaluated.